Crossmark

Efficacy and safety of rebamipide liquid for chemoradiotherapy-induced oral mucositis in patients with head and neck cancer: a multicenter, randomized, double-blind, placebo-controlled, parallel-group phase II study

Crossref DOI link: https://doi.org/10.1186/s12885-017-3295-4

Published Online: 2017-05-05

Published Print: 2017-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Yokota, T. http://orcid.org/0000-0001-7327-7949
Ogawa, T.

Takahashi, S.

Okami, K.

Fujii, T.

Tanaka, K.

Iwae, S.

Ota, I.

Ueda, T.

Monden, N.

Matsuura, K.

Kojima, H.

Ueda, S.

Sasaki, K.

Fujimoto, Y.

Hasegawa, Y.

Beppu, T.

Nishimori, H.

Hirano, S.

Naka, Y.

Matsushima, Y.

Fujii, M.

Tahara, M.
Funding

Funding for this research was provided by:

Otsuka Pharmaceutical Co., Ltd., Japan

Document is current

Any future updates will be listed below